http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101192700-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91085 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101192700-B1 |
| titleOfInvention | A Method of Screening for anti-cancer drug using TGase2 and VHL |
| abstract | In the present invention, TGase2 (Transglutaminse 2) modulates VHL (Von Hippel-Lindau) to induce HIP-1α (Hypoxia-inducible factor-1α), IGF-1α (Insulin-like growth factor receptor) and VEGF (Vascular) during cancer formation. To identify TGase2 inhibitors or promoters by determining the stability of endothelial growth factor (NF-κB) and the activity of Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and by measuring VHL protein levels or polymerization of VHL Provide a way to. Also provided are methods of detecting TGase2 inhibitors or promoters by further measuring the protein levels of HIF-1α, IGF-1R or VEGF. In the present invention, the TGase2 inhibitor may be usefully used as an anticancer agent and a TGase2 promoter as a therapeutic agent for a viral infection disease. |
| priorityDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 797.